ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D
But updated pricing model also suggests the more traditional ‘cost effectiveness’ benchmark price for remdesivir could be lower than previously estimated to account for use of dexamethasone in reducing the underlying risk of mortality in COVID-19 patients.
You may also be interested in...
With the US government currently negotiating prices and drugs mostly going to high-risk patients, ICER’s draft ‘special assessment’ of COVID treatments offers an approach to adapting research on safety and effectiveness in order to provide guidance to clinicians, payers and other stakeholders.
Coronavirus Update: Spooked By America’s COVID-19 Vaccine Skepticism, FDA Promises Not To Lower Standards
The FDA has released detailed guidance to COVID-19 vaccine manufacturers setting out the safety and efficacy standards required, and pledged to not cut corners.
Highly anticipated decision bodes well for pricing of other future treatments for the disease, the US Institute for Clinical and Economic Review suggests.